Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 18 citing articles:

The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents
Christoph U. Correll, Marco Solmi, Samuele Cortese, et al.
World Psychiatry (2023) Vol. 22, Iss. 1, pp. 48-74
Open Access | Times Cited: 82
Investigational Drugs for the Treatment of Depression (Part 1): Monoaminergic, Orexinergic, GABA-Ergic, and Anti-Inflammatory Agents
Octavian Vasiliu
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 21
New Pharmacologic Approaches to the Treatment of Bipolar Depression
Kamyar Keramatian, Trisha Chakrabarty, Anaïs DuBow, et al.
Drugs (2023) Vol. 83, Iss. 10, pp. 843-863
Closed Access | Times Cited: 8
New investigational agents for the treatment of major depressive disorder
Bartłomiej Pochwat, Anna Julia Krupa, Marcin Siwek, et al.
Expert Opinion on Investigational Drugs (2022) Vol. 31, Iss. 10, pp. 1053-1066
Closed Access | Times Cited: 13
Discovery and Model‐Informed Drug Development of a Controlled‐Release Formulation of Nonracemic Amisulpride that Reduces Plasma Exposure but Achieves Pharmacodynamic Bioequivalence in the Brain
Seth C. Hopkins, Siriporn Toongsuwan, Taryn J. Corriveau, et al.
Clinical Pharmacology & Therapeutics (2024) Vol. 116, Iss. 2, pp. 460-470
Closed Access | Times Cited: 2
A clinical trial inclusion criteria to enrich for patients presenting with canonical symptom structure in bipolar depression
Seth C. Hopkins, Sasagu Tomioka, Steven T. Szabo, et al.
Contemporary Clinical Trials (2024) Vol. 145, pp. 107644-107644
Closed Access | Times Cited: 1
Interpreting clinical trial outcomes complicated by placebo response with an assessment of false-negative and true-negative clinical trials in depression using propensity-weighting
Roberto Goméni, Seth C. Hopkins, Françoise Bressolle‐Gomeni, et al.
Translational Psychiatry (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 4
Enrichment using speech latencies improves treatment effect size in a clinical trial of bipolar depression
Joshua S. Siegel, Alex S. Cohen, Steven T. Szabo, et al.
Psychiatry Research (2024) Vol. 340, pp. 116105-116105
Closed Access | Times Cited: 1
Evaluating speech latencies during structured psychiatric interviews as an automated objective measure of psychomotor slowing
Alex S. Cohen, Zachary Rodriguez, Mark Opler, et al.
Psychiatry Research (2024) Vol. 340, pp. 116104-116104
Closed Access | Times Cited: 1
Overview of Psychiatric Medications in the Pipeline in Phase III Trials as of June 1, 2024: A Systematic Review.
Waguih William IsHak, Ashley N. D. Meyer, Luiza Freire, et al.
PubMed (2024) Vol. 21, Iss. 7-9, pp. 27-47
Closed Access | Times Cited: 1
ECG Evaluation as Part of the Clinical Pharmacology Strategy in the Development of New Drugs: A Review of Current Practices and Opportunities Based on Five Case Studies
Börje Darpö, Marie T. Borin, Georg Ferber, et al.
The Journal of Clinical Pharmacology (2022) Vol. 62, Iss. 12, pp. 1480-1500
Open Access | Times Cited: 6
A narrative review of non-racemic amisulpride (SEP-4199) for treatment of depressive symptoms in bipolar disorder and LB-102 for treatment of schizophrenia
Jie Wu, Angela T.H. Kwan, Taeho Greg Rhee, et al.
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 11, pp. 1085-1092
Closed Access | Times Cited: 3
Treat bipolar depression with atypical antipsychotics and mood stabilisers; new therapies require further study
Simon Fung
Drugs & Therapy Perspectives (2024) Vol. 40, Iss. 3, pp. 109-114
Closed Access
DSP-6745, a novel 5-hydroxytryptamine modulator with rapid antidepressant, anxiolytic, antipsychotic and procognitive effects
Maiko Kitaichi, T. KATO, Hitomi Oki, et al.
Psychopharmacology (2024)
Closed Access
PET clinical study of novel antipsychotic LB-102 demonstrates unexpectedly prolonged dopamine receptor target engagement
Dean F. Wong, Ganesh B. Chand, Nicole Caito, et al.
Neuropsychopharmacology (2024) Vol. 50, Iss. 2, pp. 372-377
Open Access
Development Progress of Drugs for Bipolar Disorder: 75 Years After Lithium Proved Effective
Keiichiro Nishida, Hitoshi Osaka, Tetsufumi Kanazawa
Journal of Psychiatric Research (2024) Vol. 180, pp. 177-182
Open Access
When to Use Amisulpride in Adolescents
Mustafa Tunçtürk, Çağatay Ermiş, Yeşim Sağlam, et al.
Journal of Clinical Psychopharmacology (2022) Vol. 42, Iss. 3, pp. 247-253
Closed Access | Times Cited: 1
Interpreting clinical trial outcomes marred by placebo response with an assessment of false-negative and true-negative clinical trials in depression using propensity-weighting
Roberto Goméni, Seth C. Hopkins, Françoise Bressolle‐Gomeni, et al.
Research Square (Research Square) (2023)
Open Access
Page 1

Scroll to top